Skip to content

13F-HR filed by Camber Capital Management LP

Camber Capital Management LP filed this 13F-HR for the quarter ended 2017-03-31, filed 2017-05-15, with 33 holding rows worth $2,465,523,000.

Accession
0001654954-17-004694
Filed
2017-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2017

A holdings report, 34 entries on the cover page, a total value of $2,465,523,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,465,523,000 with VALUE read as thousands by filing date, 13F file number 028-13745. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPY78462F103SHS3,000,000$707,220,000thousands by filing dateput
TEVA PHARMACEUTICAL INDS LTD SPONSORED ADS881624209ADR5,216,450$167,396,000thousands by filing date
MYLAN NVN59465109SHS EURO4,145,889$161,648,000thousands by filing date
Gilead Sciences,Inc.375558103COM1,900,000$129,048,000thousands by filing date
NEKTAR THERAPEUTICS640268108COM5,400,000$126,738,000thousands by filing date
ALLERGAN PLCG0177J108SHS435,750$104,109,000thousands by filing date
MYRIAD GENETICS INC62855J104COM4,325,000$83,040,000thousands by filing date
GENOMIC HEALTH, INC.37244C101COM2,458,100$77,406,000thousands by filing date
BROOKDALE SR LIVING INC112463104COM5,500,000$73,865,000thousands by filing date
Vertex Pharmaceuticals Incorporated92532F100COM650,000$71,078,000thousands by filing date
Gilead Sciences,Inc.375558103COM1,000,000$67,920,000thousands by filing datecall
SELECT MED HLDGS CORP81619Q105COM5,000,000$66,750,000thousands by filing date
BIOVERATIV INC09075E100COM1,100,000$59,906,000thousands by filing date
LIVANOVA PLCG5509L101SHS1,200,000$58,812,000thousands by filing date
ORTHOFIX INTL N VN6748L102COM1,500,000$57,225,000thousands by filing date
ENDO INTL PLCG30401106SHS5,052,000$56,380,000thousands by filing date
PERRIGO CO PLC SHSG97822103Stock808,200$53,656,000thousands by filing date
CARDIOVASCULAR SYSTEMS INC141619106COMMON STOCK1,750,000$49,481,000thousands by filing date
Abbott Laboratories002824100COM1,000,000$44,410,000thousands by filing date
ENDOLOGIX INC29266S106COM6,000,000$43,440,000thousands by filing date
ALKERMES PLCG01767105SHS725,000$42,413,000thousands by filing date
SAREPTA THERAPEUTICS INC803607100COM1,350,000$39,960,000thousands by filing date
INVITAE CORP46185L103COM2,398,123$26,523,000thousands by filing date
SYNERON MEDICAL LTDM87245102ORD2,347,593$24,767,000thousands by filing date
PUMA BIOTECHNOLOGY INC74587V107COMMON STOCK650,000$24,180,000thousands by filing date
BIOSCRIP INC09069N108COM10,180,000$17,306,000thousands by filing date
PTC THERAPEUTICS INC69366J200COM1,250,000$12,300,000thousands by filing date
BIOLASE INC090911108COMMON STOCK5,332,394$7,199,000thousands by filing date
ARENA PHARMECEUTICALS INC040047102COMMON STOCK4,250,000$6,205,000thousands by filing date
ATARA BIOTHERAPEUTICS INC COM NEW046513107Stock125,000$2,569,000thousands by filing date
TARGACEPT INC87611RAA6NOTE 2/11,684,799$1,685,000thousands by filing dateprincipal
DEXTERA SURGICAL INC COM252366109CS837,483$888,000thousands by filing date
BIOLASE INC090911108COMMON STOCK1,841,173$0thousands by filing datecallValue filed as zero, left out of ratios.

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001654954-17-004694this filing2017-05-15acceptance time not in the bulk data set